Epoetin alfa [4000 IU/mL solution for injection (IV/SC) 1 mL pre-filled syringe ] for the reduction of the period of neutropenia in patients undergoing bone marrow transplantation and for the treatment or prevention of neutropenia in pediatric patients receiving myelosuppressive cancer chemotherapy
Minor Inclusion | DrugsHTA Council Recommendation (as of 12 January 2023)
As final recommendation, the HTA Council recommends recommends the inclusion of epoetin alfa [4000 IU/mL solution for injection (IV/SC) 1 mL pre-filled syringe] for the reduction of the period of neutropenia in patients undergoing bone marrow transplantation and for the treatment or prevention of neutropenia in pediatric patients receiving myelosuppressive cancer chemotherapy in the Philippine National Formulary.
Relevant Information
- Status: With Final HTA Council Recommendation and SOH Decision
- Topic Assignment: Internal Assessment
- Policy Question: Should epoetin alfa [4000 IU/mL solution for injection (IV/SC) 1 mL pre-filled syringe] for the reduction of the period of neutropenia in patients undergoing bone marrow transplantation and for the treatment or prevention of neutropenia in pediatric patients receiving myelosuppressive cancer chemotherapy be funded by the government?
- Secretary of Health Decision: Approved as of 01 February 2023
Evidence and Relevant Documents